Cargando…

Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor

BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor that promotes cell proliferation and immunomodulation in untransformed cells and maintains stemness of transformed cells, facilitating invasion and metastasis. Numerous point mutations in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Behrendsen, Lena Sophie, Menon, Priyanka Rajeev, Khan, Muhammad Jawad, Gregus, Anke, Wirths, Oliver, Meyer, Thomas, Staab, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233852/
https://www.ncbi.nlm.nih.gov/pubmed/35752777
http://dx.doi.org/10.1186/s12860-022-00422-9
_version_ 1784735901682761728
author Behrendsen, Lena Sophie
Menon, Priyanka Rajeev
Khan, Muhammad Jawad
Gregus, Anke
Wirths, Oliver
Meyer, Thomas
Staab, Julia
author_facet Behrendsen, Lena Sophie
Menon, Priyanka Rajeev
Khan, Muhammad Jawad
Gregus, Anke
Wirths, Oliver
Meyer, Thomas
Staab, Julia
author_sort Behrendsen, Lena Sophie
collection PubMed
description BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor that promotes cell proliferation and immunomodulation in untransformed cells and maintains stemness of transformed cells, facilitating invasion and metastasis. Numerous point mutations in the STAT3 protein have been identified that drive malignancy in various tumor entities. The missense mutation D427H localized in the STAT3 DNA-binding domain has been previously reported in patients with NK/T cell lymphomas. To assess the biological activity of this missense mutation, we compared the STAT3-D427H mutant to wild-type (WT) protein as well as the known hyper-active mutant F174A. RESULTS: Although previously reported as an activating mutation, the STAT3-D427H mutant neither showed elevated cytokine-induced tyrosine phosphorylation nor altered nuclear accumulation, as compared to the WT protein. However, the D427H mutant displayed enhanced binding to STAT-specific DNA-binding sites but a reduced sequence specificity and dissociation rate from DNA, which was demonstrated by electrophoretic mobility shift assays. This observation is consistent with the phenotype of the homologous E421K mutation in the STAT1 protein, which also displayed enhanced binding to DNA but lacked a corresponding increase in transcriptional activity. CONCLUSIONS: Based on our data, it is unlikely that the D427H missense mutation in the STAT3 protein possesses an oncogenic potential beyond the WT molecule. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12860-022-00422-9.
format Online
Article
Text
id pubmed-9233852
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92338522022-06-27 Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor Behrendsen, Lena Sophie Menon, Priyanka Rajeev Khan, Muhammad Jawad Gregus, Anke Wirths, Oliver Meyer, Thomas Staab, Julia BMC Mol Cell Biol Research BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor that promotes cell proliferation and immunomodulation in untransformed cells and maintains stemness of transformed cells, facilitating invasion and metastasis. Numerous point mutations in the STAT3 protein have been identified that drive malignancy in various tumor entities. The missense mutation D427H localized in the STAT3 DNA-binding domain has been previously reported in patients with NK/T cell lymphomas. To assess the biological activity of this missense mutation, we compared the STAT3-D427H mutant to wild-type (WT) protein as well as the known hyper-active mutant F174A. RESULTS: Although previously reported as an activating mutation, the STAT3-D427H mutant neither showed elevated cytokine-induced tyrosine phosphorylation nor altered nuclear accumulation, as compared to the WT protein. However, the D427H mutant displayed enhanced binding to STAT-specific DNA-binding sites but a reduced sequence specificity and dissociation rate from DNA, which was demonstrated by electrophoretic mobility shift assays. This observation is consistent with the phenotype of the homologous E421K mutation in the STAT1 protein, which also displayed enhanced binding to DNA but lacked a corresponding increase in transcriptional activity. CONCLUSIONS: Based on our data, it is unlikely that the D427H missense mutation in the STAT3 protein possesses an oncogenic potential beyond the WT molecule. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12860-022-00422-9. BioMed Central 2022-06-25 /pmc/articles/PMC9233852/ /pubmed/35752777 http://dx.doi.org/10.1186/s12860-022-00422-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Behrendsen, Lena Sophie
Menon, Priyanka Rajeev
Khan, Muhammad Jawad
Gregus, Anke
Wirths, Oliver
Meyer, Thomas
Staab, Julia
Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor
title Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor
title_full Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor
title_fullStr Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor
title_full_unstemmed Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor
title_short Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor
title_sort evaluation of the putative lymphoma-associated point mutation d427h in the stat3 transcription factor
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233852/
https://www.ncbi.nlm.nih.gov/pubmed/35752777
http://dx.doi.org/10.1186/s12860-022-00422-9
work_keys_str_mv AT behrendsenlenasophie evaluationoftheputativelymphomaassociatedpointmutationd427hinthestat3transcriptionfactor
AT menonpriyankarajeev evaluationoftheputativelymphomaassociatedpointmutationd427hinthestat3transcriptionfactor
AT khanmuhammadjawad evaluationoftheputativelymphomaassociatedpointmutationd427hinthestat3transcriptionfactor
AT gregusanke evaluationoftheputativelymphomaassociatedpointmutationd427hinthestat3transcriptionfactor
AT wirthsoliver evaluationoftheputativelymphomaassociatedpointmutationd427hinthestat3transcriptionfactor
AT meyerthomas evaluationoftheputativelymphomaassociatedpointmutationd427hinthestat3transcriptionfactor
AT staabjulia evaluationoftheputativelymphomaassociatedpointmutationd427hinthestat3transcriptionfactor